References
- Ibrahim E. H., Sherman G., Ward S., et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118: 146–55
- Spellberg B., Powers J. H., Brass E. P., et al. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 2004; 38: 1279–86
- Petersen P. J., Jacobus N. V., Weiss W. J., et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9‐t‐butylglycylamido derivative of minocycline (GAR‐936). Antimicrob Agents Chemother 1999; 43: 738–44
- Pachόn‐Ibáńez M. E., Jiménez‐Mejías M. E., Pichardo C., et al. Activity of tigecycline (GAR‐936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Agents Chemother 2004; 48: 4479–81
- Peleg A. Y., Franklin C., Spelman D. W., et al. Dissemination of the metallo‐β‐lactamases gene blaIMP‐4 among gram‐negative pathogens in a clinical setting in Australia. Clin Infect Dis 2005; 41: 1549–56
- Herbert S., Halvorsen D., Leong T., et al. Large outbreak of infection and colonization with gram‐negative pathogens carrying the metallo‐B‐lactamase gene blaIMP‐4 at a 320 bed tertiary hospital teaching hospital in Australia. Infect Control Epidemiol 2007; 28: 98–101
- Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; 15th Informational Supplement. CLSI, Wayne, PA 2005, CLSI document M100‐S‐15
- Pitout J. D. D., Reisbig M. D., Venter E. C., et al. Modification of the Double‐Disk test for detection of Enterobacteriaceae producing extended‐spectrum and AmpC β‐Lactamases. J Clin Microbiol 2003; 41: 3933–5
- Franklin C., Liolios L., Peleg A. Y. Phenotypic detection of carbapenem‐susceptible metallo‐β‐lactamase‐producing gram‐negative bacilli in the clinical laboratory. J Clin Microbiol 2006; 44: 3139–44
- Catchpole J. R., Andrews J. M., Brenwald N., et al. A reassessment of the in‐vitro activity of colistin sulphomethate sodium. J Antimicrob Chemother 1997; 39: 255–60
- Hoban D. J., Bouchillon S. K., Johnson B. M., et al. In vitro activity of tigecycline against 6792 gram‐negative and gram‐positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn Microbiol Infect 2005; 52: 215–27
- Dean C. R., Visalli M. A., Projan S. J., et al. Efflux‐mediated resistance to tigecycline (GAR‐936) in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother 2003; 47: 972–8
- Schulin T. In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany. J Antimicrob Chemother 2002; 49: 403–6
- Koch‐Weser J., Federman E. B., Kanarek P., et al. Adverse effects of sodium colistimethate: manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970; 72: 857–68